29 November 2016 : The collaboration will explore the expression of OAcGD2 antigen in tumors from patients with glioblastoma and the potential of anti-OACGD2 monoclonal antibodies to treat a panel of resistant glioblastoma tumors, alone or in combination with standard treatments such as temozolomide and irradiation. Pr. Weller’s team will first conduct efficacy studies in preclinical models with anti-OAcGD2 monoclonal antibodies, with the perspective of initiating a first-in-human clinical trial for relapsing glioblastoma patients.
“As detailed in our recent strategic update, OGD2 Pharma continues exploring the potential of therapies targeting the OAcGD2 antigen in various cancers. This collaboration follows a first proof of concept study conducted in animal models and published in 2016 (Fleurence et al, 2016)” said Jean Marc Le Doussal, President at OGD2 Pharma.
Press Release : ogd2-university-of-zurich-pr-2016-11-29-release
6 September 2016 : This collaboration agreement will explore the potential of targeting chemotherapeutic drugs using anti-OAcGD2 ADCs in the treatment of difficult-to-treat solid tumors. The ADCs will be designed to release the cytotoxic drug both within tumor cells and in the tumor microenvironment.
“Thanks to this collaboration, OGD2 Pharma accelerates the development of its anti-OAcGD2 ADC platform. Syndivia’s versatile linker technology will allow depicting the best way to specifically deliver ADC payloads to tumors using the unique cellular biology of the OAcGD2 membrane glycolipid” said Jean-Marc Le Doussal, President at OGD2 Pharma. “Syndivia’s technology should result in ADCs that are highly stable in patient’s blood, in line with our strategy to develop safer anti-cancer therapies leveraging the highly tumor-specific tissue distribution of the OAcGD2 antigen. OGD2 Pharma will continue building such strategic partnerships with academic groups and private companies in other ADC technologies.” he added.
Press release : OGD2 SYNDIVIA PR 2016 09 06 release
22 June 2016 : With this collaboration, OGD2 Pharma and GCLC will explore the potential of targeting NK-cells to the OAcGD2 antigen using humanized antibody and chimeric antigen receptors (CAR) for fighting against solid tumors.
“Thanks to this collaboration OGD2 Pharma speeds-up the development of its anti-OAcGD2 CAR platform. We highly value Green Cross leadership in allogenic NK-cell therapy and their proven ability to develop and to market cell therapy products” said Jean-Marc Le Doussal, President at OGD2 Pharma. “OGD2 Pharma will continue building strategic partnerships with academic groups and private companies in other fields of cell therapies.” he added.
Press release: OGD2 GCLC PR 2016 06 22 release